PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849151 / 7457217 Sample Receive Date : 16/Jun/2023 02:22PM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA Report Date : 16/Jun/2023 06:14PM

HAEMATOLOGY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Glycosylated Hemoglobin (HbA1c) 5.7 % 4 - 5.6 HPLC

Estimated average glucose (eAG) 116.89 mg/dL Calculated

Comment:
Interpretation: HbA1c%

≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes

Adapted from American Diabetes Association.

Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.

Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.

• HPLC - High performance liquid chromatography

Page 1 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849151 / 7457217 Sample Receive Date : 16/Jun/2023 02:22PM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 16/Jun/2023 09:14PM

HAEMATOLOGY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 13.4 g/dL 13.0-17.0 Cyanide Free SLS
RBC 4.70 10^6/cu.mm 4.5 - 5.5 Impedance
HCT 42.3 % 40 - 50 Calculated
MCV 90.1 fL 83 - 101 RBC pulse measurement
MCH 28.5 pg 27 - 32 Calculated
MCHC 31.7 g/dL 31.5 - 34.5 Calculated
RDW-CV 15.9 % 11.6-14 Calculated
Total Leucocyte Count 7.27 10^3/µL 4 - 10 Impedance
Differential Leucocyte Count
Neutrophils 40.5 % 40-80 Flowcytometery DHHS/
Microscopy
Lymphocytes 50.0 % 20-40 Flowcytometery DHHS/
Microscopy
Monocytes 6.5 % 2-10 Flowcytometery DHHS/
Microscopy
Eosinophils 2.4 % 1-6 Flowcytometery DHHS/
Microscopy
Basophils 0.6 % 0-2 Impedance / Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 2.94 10^3/µL 2-7 Calculated
Absolute Lymphocyte Count 3.64 10^3/µL 1-3 Calculated
Absolute Monocyte Count 0.47 10^3/µL 0.2-1 Calculated
Absolute Eosinophil Count 0.17 10^3/µL 0.02-0.5 Calculated
Absolute Basophil Count 0.04 10^3/µL 0.02-0.1 Calculated
Platelet Count 150 10^3/µL 150-410 Impedance /Microscopy
MPV 12.5 fL 6.5 - 12 Calculated
PDW 30 fL 9-17 Calculated

Comment:

Page 2 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849151 / 7457217 Sample Receive Date : 16/Jun/2023 02:22PM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 16/Jun/2023 09:14PM

HAEMATOLOGY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts
are additionally being reported as absolute numbers of each cell in per unit volume of blood.

Page 3 of 13
 PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849149 / 7457217 Sample Receive Date : 16/Jun/2023 02:28PM
Referred By : Dr. Report Status : Final Report
Sample Type : Fluoride Plasma F Report Date : 16/Jun/2023 06:36PM

BIOCHEMISTRY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Glucose - Fasting
Glucose - Fasting 97 mg/dL 70-99 Hexokinase/G-6-PDH

Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes

Reference : American Diabetes Association

Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
Less than 7%
HbA1c

Page 4 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 04:12PM

BIOCHEMISTRY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 192 mg/dL Desirable <200, Enzymatic
Borderline High 200-239,
High >=240
Triglycerides 86 mg/dL Normal: <150, GPO
Borderline: 150 - 199,
High:200-499,
Very High>=500
Cholesterol - HDL 43 mg/dL Undesirable/high risk Elimination/catalase
<=40mg/dL
Desirable/low
risk>=60mg/dl
Cholesterol - LDL 132 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 17 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 4.4 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 3.04 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 149 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220

Page 5 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 04:12PM

BIOCHEMISTRY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Comment:

Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age; more
severe in nature and have high mortality.
Major risk factors have been found to be dyslipidemia (abnormal lipid profile), smoking, sedentary lifestyle, obesity,
hypertension and diabetes. Dyslipidemia is most important and found to be very high in Indians (79%); hence control of
dyslipidemia is the key healthcare target.
LDL-Cholesterol (LDL-C) contributes most significantly to atherosclerosis and is the primary target of treatment.
Triglyceride (TG) rich lipoprotein remnants also play a major role in CVD. Indians have higher triglyceride levels and lower
HDL-C (good cholesterol) combined with increased proportion of small dense LDL-C; this pattern is called atherogenic
dyslipidemia and is associated with diabetes, metabolic syndrome and insulin resistance.
Non-HDL-Cholesterol (Non-HDLC) measures all atherogenic lipoproteins (LDL-C, VLDL, Lp(a), Apo-B). Monitoring of Non-
HDLC is the co-primary target and is especially important in patients with elevated TG (e.g. diabetics, obese persons,
metabolic syndrome) and those on statin therapy.
Lipid Association of India (LAI) recommendations (2020) -
Screening of all Indians above the age of 20 years for CVD risk factors esp. lipid profile.
Risk factors known to promote atherosclerosis include: Age- male ≥45 years, female ≥55 years; Family h/o
premature CAD (male <55 years, female <65 years), Smoking/tobacco use, Systemic hypertension, Low HDL (males
<40 mg/dl and females <50 mg/dl.
Fasting lipid profile is not mandatory. Both fasting and non-fasting lipid profiles are important for managing Indian
patients with dyslipidemia. Non-HDLC should be calculated in every subject.
Newer treatment goals have been laid down based on different risk categories (According to LAI algorithm). LAI
recommends LCD-C as primary target and Non-HDL as co-primary treatment target.
Lifestyle modifications are integral for management and prevention of dyslipidemia.
In low risk patients, consider therapy after an initial non-pharmacological intervention for at least 3 months.
Additional testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered among patients with moderate risk for
ASCVD for risk refinement

Note: Reference Interval as per National Cholesterol Education Program (NCEP) ATP-III Report.

Page 6 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 06:35PM

BIOCHEMISTRY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Liver Function Test

Bilirubin-Total 0.46 mg/dl 0.3 – 1.2 Vanadate oxidation
Bilirubin-Direct 0.15 mg/dl 0 - 0.3 Vanadate oxidation
Bilirubin-Indirect 0.31 mg/dL 0.2-0.8 Calculated
Protein, Total 7.49 g/dL 5.7-8.2 Biuret
Albumin 4.89 g/dL 3.4-4.8 BCG Dye Binding
Globulin 2.6 g/dl 2.1 - 3.9 Calculated
A/G Ratio 1.88 Ratio 0.8 - 2.1 Calculated
Aspartate Transaminase (SGOT) 28 U/L <34 Modified IFCC
Alanine Transaminase (SGPT) 45 U/L 10-49 Modified IFCC
SGOT/SGPT 0.62 Ratio <1 Calculated
Alkaline Phosphatase 81 U/L 46-116 IFCC Standardization
Gamma Glutamyltransferase (GGT) 32 U/L <73 Modified IFCC

Comment:
•LFTS are based upon measurements of substances released from damaged hepatic cells into the blood that gives idea of the
Existence, Extent and Type of Liver damage. - Acute Hepatocellular damage: ALT & AST levels are sensitive index of
hepatocellular damage - Obstruction to the biliary tract,Cholestasis and blockage of bile flow:1) Serum Total Bilirubin
concentration 2) Serum Alkaline Phosphatase (ALP) activity 3) Gamma Glutamyl Transpeptidase (GGTP) 4) 5`-Nucleotidase -
Chronic liver disease: Serum Albumin concentration
•Bilirubin results from the enzymatic breakdown of heme. Jaundice is a yellowish discoloration of the skin and mucous
membranes caused by hyperbilirubinemia.
•Pre-hepatic or hemolytic jaundice - Abnormal red cells, antibodies,drugs and toxins,Hemoglobinopathies, Gilbert’s syndrome,
Crigler-Najjar syndrome
•Hepatic or Hepatocellular jaundice-Viral hepatitis,toxic hepatitis, intrahepatic cholestasis
•Post-hepatic jaundice -Extrahepatic cholestasis, gallstones, tumors of the bile duct, carcinoma of pancreas
•In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT concentrations are
elevated even before the clinical signs and symptoms of disease appear.
•ALT is the more liver-specific enzyme and elevations of ALT activity persist longer than AST activity.
•Peak values of aminotransferase activity occur between the seventh and twelfth days. Activities then gradually decrease,
reaching normal activities by the third to fifth week. Peak activities bear no relationship to prognosis and may fall with worsening
of the patient's condition.
•Aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper
reference limit to four to five times higher, with an AST/ALT ratio greater than 1. The ratio's elevation can reflect the grade of
fibrosis in these patients. Slight or moderate elevations of both AST and ALT activities have been observed after administration
of various medications and chronic hepatic injury such as (1) hemochromatosis, (2) Wilson disease, (3) autoimmune hepatitis, (4)
primary biliary cirrhosis, (5) sclerosing cholangitis, and (6) a1-antitrypsin deficiency.
•AST activity also is increased in acute myocardial infarction, progressive muscular dystrophy and dermatomyositis, reaching

Page 7 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 06:35PM

BIOCHEMISTRY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

concentrations up to eight times the upper reference limit.Slight to moderate AST elevations are noted in hemolytic disease.
•GGT is a sensitive indicator of the presence of hepatobiliary disease, being elevated in most subjects with liver disease
regardless of cause. Increased concentrations of the enzyme are also found in serum of subjects receiving anticonvulsant drugs,
such as phenytoin and phenobarbital.

Page 8 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 06:47PM

BIOCHEMISTRY
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Kidney Function Test.

Blood Urea Nitrogen 11 mg/dL 9-23 Urease with GLDH
Urea 23.54 mg/dl 19.26-49.22 Calculated
Creatinine 0.97 mg/dL 0.70-1.30 Alkaline picrate - kinetic
Uric Acid 7.9 mg/dL 3.5-7.2 Uricase/Peroxidase
Sodium 143 mmol/L 132-146 Indirect ISE
Potassium 4.80 mmol/L 3.5-5.5 Indirect ISE
Chloride 108.0 mmol/L 99-109 Indirect ISE
BUN/Creatinine Ratio 11.3 Ratio 12:1 - 20:1 Calculated

Comment:
BUN is directly related to protein intake and nitrogen metabolism and inversely related to the rate of excretion of urea.Blood
urea nitrogen (BUN) levels reflect the balance between the production and excretion of urea. Increased levels are seen in renal
failure (acute or chronic), urinary tract obstruction, dehydration, shock, burns, CHF, GI bleeding, nephrotoxic drugs. Decreased
levels are seen in hepatic failure, nephrotic syndrome, cachexia (low-protein and high-carbohydrate diets).
Urea is a non-proteinous nitrogen compound formed in the liver from ammonia as an end product of protein metabolism. Urea
diffuses freely into extracellular and intracellular fluid and is ultimately excreted by the kidneys. Increased levels are found in
acute renal failure, chronic glomerulonephritis, congestive heart failure, decreased renal perfusion, diabetes, excessive protein
ingestion, gastrointestinal (GI) bleeding, hyperalimentation, hypovolemia, ketoacidosis, muscle wasting from starvation,
neoplasms, pyelonephritis, shock, urinary tract obstruction, nephrotoxic drugs. Decreased levels are seen in inadequate dietary
protein, low-protein/high-carbohydrate diet, malabsorption syndromes, pregnancy, severe liver disease, certain drugs.
Creatinine is catabolic product of creatinine phosphate, which is excreted by filtration through the glomerulus and by tubular
secretion. Creatinine clearance is an acceptable clinical measure of glomerular filtration rate (GFR). Increased levels are seen in
acute/chronic renal failure, urinary tract obstruction, hypothyroidism, nephrotoxic drugs, shock, dehydration, congestive heart
failure, diabetes. Decreased levels are found in muscular dystrophy.
BUN/Creatinine ratio (normally 12:1–20:1) is decreased in acute tubular necrosis, advanced liver disease, low protein intake,
and following hemodialysis. BUN/Creatinine ratio is increased in dehydration, GI bleeding, and increased catabolism.
Uric acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels are
seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout, renal disorders, increased breakdown of body cells
in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia, sickle cell
anemia, or heart failure, pre-eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood levels of
parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats, some seafood
and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate antidiuretic hormone (SIADH),
certain drugs.

Page 9 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 06:03PM

Immunology
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Thyroid Stimulating Hormone - Ultra 2.287 uIU/ml 0.55-4.78 CLIA

Sensitive

Comment:

Reference ranges for TSH (μIU/ml) [As per American thyroid

Pregnancy
Association]
1st
0.1-2.5
trimester
2nd
0.2-3.0
trimester
3rd
0.3-3.0
trimester

TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection
or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
For the diagnosis of hypothyroidism and hyperthyroidism, sole dependence on TSH should not be done and assay needs
to be interpreted with the clinical condition & other investigations.
Serum TSH level changes significantly in response to even minor changes in thyroid hormones.
Transient increase in TSH level or an abnormal TSH levels can be seen in various nonthyroidal diseases.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.

Page 10 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 06:03PM

Immunology
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

TSH T3 T4 Interpretation
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low
Hypothyroidism

Page 11 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 04:14PM

Immunology
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Vitamin D (25-OH) 41.5 ng/mL Deficiency:< 20, CLIA

Insufficiency:20-29,
Sufficiency:30 - 100,
Toxicity possible:> 100

Comment:

Vitamin D is a fat-soluble steroid prohormone involved in the intestinal absorption of calcium and the regulation of calcium
homeostasis.
Two forms of vitamin D are biologically relevant - vitamin D3 (Cholecalciferol) and vitamin D2 (Ergocalciferol).
Both vitamins D3 and D2 can be absorbed from food but only an estimated 10-20perc. of vitamin D is supplied through
nutritional intake.
Vitamin D is converted to the active hormone 1,25-(OH)2-vitamin D (Calcitriol) through two hydroxylation reactions. The
first hydroxylation converts vitamin D into 25-OH vitamin D and occurs in the liver. The second hydroxylation converts 25-
OH vitamin D into the biologically active 1,25-(OH)2-vitamin D and occurs in the kidneys as well as in many other cells of
the body.
Most cells express the vitamin D receptor and about 3perc. of the human genome is directly or indirectly regulated by the
vitamin D endocrine system.
The major storage form of vitamin D is 25-OH vitamin D and is present in the blood at up to 1,000 fold higher
concentration compared to the active 1,25-(OH)2-vitamin D. 25-OH vitamin D has a half-life of 2-3 weeks vs. 4 hours for
1,25-(OH)2-vitamin D. Therefore, 25-OH vitamin D is the analyte of choice for determination of the vitamin D status.
Risk factors for vitamin D deficiency include low sun exposure, inadequate intake, decreased absorption, abnormal
metabolism, vitamin D resistance and and liver or kidney diseases.
Vitamin D deficiency is a cause of secondary hyperparathyroidism and diseases resulting in impaired bone metabolism (like
rickets, osteomalacia).
Recently, many chronic diseases such as cancer, high blood pressure, osteoporosis and several autoimmune diseases
have been linked to vitamin D deficiency.
The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D

Utility Quantitative determination of 25-hydroxyvitamin D (25-OH vitamin D).

Page 12 of 13
PO No :CUPC-21

Name : Mr.ADARSH TIWARI Client Name : TATA 1MG OKHLA

Age/Gender : 49/Male Registration Date : 16-Jun-23 02:01 PM
Patient ID : OKH773667 Collection Date : 16/Jun/2023 02:01PM
Barcode ID/Order ID : D4849152 / 7457217 Sample Receive Date : 16/Jun/2023 02:25PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 16/Jun/2023 06:17PM

Immunology
HEALTH PACKAGE FASTING
Test Name Result Unit Bio. Ref. Interval Method

Vitamin B12 165.0 pg/ml 211 - 911 CLIA

Comment:

Vitamin B12 along with folate is essential for DNA synthesis and myelin formation.
Decreased levels a r e s e e n i n a n a e m i a , t e r m p r e g n a n c y , v e g e t a r i a n d i e t , i n t r i n s i c f a c t o r d e f i c i e n c y , p a r t i a l
gastrectomy/ileal damage, celiac disease, oral contraceptive use, parasitic infestation, pancreatic deficiency, treated
epilepsy, smoking, hemodialysis and advanced age.
Increased levels are seen in renal failure, hepatocelluar disorders, myeloproliferative disorders and at times with excess
supplementation of vitamins pills.

*** End Of Report ***

Page 13 of 13
 TATA1mg Labs
NABL certificate
and Scope

THANK YOU
for choosing us as your healthcare partner
Tata 1mg Labs, India's trusted diagnostics lab chain, is serving over a million customers each year across
50+ cities. We offer a broad range of tests through an extensive catalog and cutting-edge technology. Our
commitment to providing high-quality healthcare is supported by 11 state-of-the-art laboratories, ensuring
easy access to our services across the country.

Q Delhi (National Reference Lab) Q Gurgaon Q Mumbai Q Pune Q Kolkata

Q Lucknow Q Ahmadabad Q Bangalore Q Chennai Q Hyderabad Q Dehradun

Our Promise
Hygienic In accordance with Expert team Doctor-verified
sample international norms & of medical reports with 3-step
collection clinical safetystandards professionals review process

Get FREE doctor consultation

on every lab test
Watch how
1A1A@ilto
Consult top doctors we take care of
from the comfort of your home your sample

CLAIM NOW>

Introducing TATA 1mg

Cancer Care Platf Need more help?

One stop for comprehensive cancer assistance
Information on specialty medicines, oncologists in your city, Callon
diagnostic tests, PSPs & more
1800-102-1618
EXPLORE NOW >

Conditions of Laboratory Testing & Reporting:

Test results released pertain to the sample, as received. laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be
clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report may vary
depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal purposes. Please mail
your queries related to test results to Customer Care mall ID cs.labs@lmg.com

Disclaimer: Results re/ate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All lab test
results are subject to clinical interpretation by a qualified medico/ professional. This report cannot be used for any medico-legal purposes. Partial
reproduction of the test results is not permitted. Also, TA TA 1mg Lobs is not responsible for any misinterpretation or misuse of the information. The test
reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be vetted by o qualified doctor only.